MedTrace Logo

Doxorubicin Pharmacokinetic (PK) Study

NCT00124956 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-09-11

No results posted yet for this study

Summary

This protocol is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 9 children will be enrolled at Children's Hospital Boston. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population.

Conditions

Interventions

DRUG

Doxorubicin

Sponsors & Collaborators

  • Glaser Pediatric Research Network

    collaborator NETWORK

  • Elizabeth Glaser Pediatric AIDS Foundation

    collaborator OTHER

  • Boston Children's Hospital

    lead OTHER

Principal Investigators

  • Holcombe Grier, MD · Dana Farber Cancer Insitute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00124956 on ClinicalTrials.gov